Fake Cancer Drug Plot: Man Sentenced After Selling 'Keytruda' That Was 'Just Like Water'

A Massachusetts federal court has sentenced an Indian national to more than three years in prison after he admitted to conspiring with others to sell a counterfeit version of the cancer drug Keytruda, which contained none of the medication's life‑saving active ingredient, prosecutors said. The shocking case highlights the dangers of illicit drug supply networks and the potential harm to vulnerable patients.

The US Department of Justice (DOJ) announced that Sanjay Kumar, 45, of India, was sentenced to 43 months in prison followed by three years of supervised release after pleading guilty to one count of conspiracy to traffic in a counterfeit drug intended to treat advanced cancer.

Plot to Sell Counterfeit Cancer Medication

Prosecutors described how Kumar and his co‑conspirators sold vials falsely labelled as the immunotherapy drug Keytruda to consumers in the United States, often through online marketplaces. Keytruda, whose generic name is pembrolizumab, is an expensive and widely used therapy for advanced melanoma and other cancers when standard treatment has failed.

Federal authorities established that the vials distributed by Kumar's network did not contain pembrolizumab, meaning patients who used them received no therapeutic benefit. In some cases, investigators said, the substances in the vials were 'just like water,' underscoring how far removed the fake product was from legitimate medicine.

According to prosecutors, crimes like this are particularly egregious because they target individuals battling life‑threatening illnesses with false hope and substandard substitutes for an approved therapy.

The sentencing came after a lengthy investigation involving the Drug Enforcement Administration (DEA), the Food and Drug Administration (FDA), and other federal agencies that monitored the illicit distribution of unapproved cancer drugs.

How the Scheme Worked

Investigators uncovered that Kumar was part of an international conspiracy that smuggled counterfeit Keytruda into the United States. Although the drugs were labelled to appear authentic, laboratory testing confirmed they contained no active anticancer ingredients.

Many of the patients who obtained the fake drug believed they were receiving legitimate cancer treatment, a misconception fuelled by the criminal group's deliberate mislabelling and deceptive marketing. The scheme preyed on the desperation of individuals seeking cutting‑edge therapies, especially those unable to afford or access treatment through standard medical channels.

The DOJ's press release noted that the conspiracy generated hundreds of thousands of dollars and involved 'significant quantities' of counterfeit vials shipped in from overseas locations. The illicit distribution network operated largely through digital channels that made detection more difficult for authorities.

Victims' Risk and Public Health Concerns

Medical experts have warned that counterfeit cancer drugs pose a severe risk to patients because they may not only be ineffective but could introduce contaminants or unsafe substances into the body.

Legitimate cancer therapies like Keytruda undergo rigorous testing and quality control before reaching patients. However, protections like this are entirely absent in black‑market products.

During the sentencing hearing, prosecutors underscored that the conspiracy's deliberate deception went beyond financial fraud, affecting people at their most vulnerable.

Broader Implications for Drug Safety

The case against Kumar underscores broader challenges facing regulators and health authorities as criminal networks attempt to exploit demand for expensive oncology drugs. Legitimate cancer medication costs can run into tens of thousands of dollars per treatment course, incentivising some patients to seek cheaper alternatives online.

However, physicians and public‑health experts warn that circumventing medical supervision can result in delayed treatment, disease progression, and avoidable harm. The proliferation of counterfeit drugs poses a direct threat to cancer patients already contending with serious illness.

Federal authorities have responded by increasing international cooperation and leveraging digital surveillance to identify illicit pharmacies, fake drug listings, and criminal syndicates trafficking in counterfeit medical products.